AI Governance in Pharma: Ethics by Design for Quality Leaders

AI governance in the pharmaceutical industry cannot begin after deployment.

By that point, critical decisions about data, accountability, human oversight, transparency, risk, and system behavior have already been embedded into the technology.

So the better question is:

What if ethics were designed into AI from the beginning?

In this episode of The GMP Insider, we explore the concept of Ethics by Design and why it could become a foundational pillar of responsible AI governance in pharmaceutical Quality.

Discussion topics include:

Why AI governance must begin during system design

Patient safety considerations when AI makes mistakes

Transparency and understanding AI outputs

Designing meaningful human oversight

Data integrity and AI governance

Identifying potential bias and unintended outcomes